[go: up one dir, main page]

NO20021452L - Orale kontrollerte frigivelsesformuleringer - Google Patents

Orale kontrollerte frigivelsesformuleringer

Info

Publication number
NO20021452L
NO20021452L NO20021452A NO20021452A NO20021452L NO 20021452 L NO20021452 L NO 20021452L NO 20021452 A NO20021452 A NO 20021452A NO 20021452 A NO20021452 A NO 20021452A NO 20021452 L NO20021452 L NO 20021452L
Authority
NO
Norway
Prior art keywords
controlled release
release formulations
oral controlled
oral
formulations
Prior art date
Application number
NO20021452A
Other languages
English (en)
Other versions
NO331480B1 (no
NO20021452D0 (no
Inventor
Rajen Shah
Satish Chandra Khanna
Oskar Kalb
Joerg Ogorka
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10861819&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20021452(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of NO20021452D0 publication Critical patent/NO20021452D0/no
Publication of NO20021452L publication Critical patent/NO20021452L/no
Publication of NO331480B1 publication Critical patent/NO331480B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO20021452A 1999-09-29 2002-03-22 Farmasoytiske sammensetninger med kontrollert frigivelse NO331480B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9923045.0A GB9923045D0 (en) 1999-09-29 1999-09-29 New oral formulations
PCT/EP2000/009455 WO2001022944A1 (en) 1999-09-29 2000-09-27 Oral controlled release formulations

Publications (3)

Publication Number Publication Date
NO20021452D0 NO20021452D0 (no) 2002-03-22
NO20021452L true NO20021452L (no) 2002-03-22
NO331480B1 NO331480B1 (no) 2012-01-16

Family

ID=10861819

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20021452A NO331480B1 (no) 1999-09-29 2002-03-22 Farmasoytiske sammensetninger med kontrollert frigivelse

Country Status (31)

Country Link
US (2) US20060246101A1 (no)
EP (1) EP1216032B1 (no)
JP (1) JP2003510268A (no)
KR (2) KR20050100710A (no)
CN (1) CN1213737C (no)
AR (1) AR025792A1 (no)
AT (1) ATE384517T1 (no)
AU (1) AU769646B2 (no)
BR (1) BR0014440A (no)
CA (1) CA2379595A1 (no)
CO (1) CO5210867A1 (no)
CY (1) CY1107923T1 (no)
CZ (1) CZ301455B6 (no)
DE (1) DE60037897T2 (no)
DK (1) DK1216032T3 (no)
EC (1) ECSP003685A (no)
ES (1) ES2299438T3 (no)
GB (1) GB9923045D0 (no)
HU (1) HUP0202744A3 (no)
IL (2) IL148908A0 (no)
MY (1) MY128759A (no)
NO (1) NO331480B1 (no)
NZ (1) NZ517335A (no)
PE (1) PE20010568A1 (no)
PL (1) PL200822B1 (no)
PT (1) PT1216032E (no)
RU (1) RU2281758C2 (no)
SK (1) SK286651B6 (no)
TR (1) TR200200683T2 (no)
WO (1) WO2001022944A1 (no)
ZA (1) ZA200202369B (no)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8679533B2 (en) 2002-07-25 2014-03-25 Pharmacia Corporation Pramipexole once-daily dosage form
EP2431027A1 (en) 2004-08-13 2012-03-21 Boehringer Ingelheim International GmbH Extended release pellet formulation containing Pramipexole or a pharmaceutically acceptable salt thereof, method for manufacturing the same and use thereof
ATE486588T1 (de) 2004-08-13 2010-11-15 Boehringer Ingelheim Int Tablettenformulierung mit verlängerter freisetzung mit pramipexol oder einem pharmazeutisch zulässigen salz davon, herstellungsverfahren und verwendung dafür
JP2008525313A (ja) * 2004-12-27 2008-07-17 エーザイ・アール・アンド・ディー・マネジメント株式会社 抗痴呆薬の安定化方法
GB0606562D0 (en) * 2006-03-31 2006-05-10 Novartis Ag Organic compounds
CN101797236B (zh) * 2010-03-23 2012-05-23 西南大学 重酒石酸卡巴拉汀口腔崩解片及其制备方法
AU2011305572B2 (en) 2010-09-20 2016-08-04 Diane Goll Microencapsulation process and product
KR101990951B1 (ko) 2015-04-27 2019-06-20 주식회사 네비팜 리바스티그민 함유 서방출 의약조성물
CN106000294B (zh) * 2016-07-04 2019-04-30 三峡大学 一种高膨胀低收缩率膨润土及制备方法
CN115192538B (zh) * 2022-08-02 2023-09-15 沈阳信康药物研究有限公司 一种压制包衣型硝苯地平缓释片及其制备方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8404467D0 (sv) * 1984-09-06 1984-09-06 Ferrosan Ab Controlled-release medical preparations
IL74497A (en) * 1985-03-05 1990-02-09 Proterra Ag Pharmaceutical compositions containing phenyl carbamate derivatives and certain phenyl carbamate derivatives
DE3805744C2 (de) * 1987-03-04 1999-09-23 Novartis Ag Phenylcarbamate zur Hemmung der Acetylcholinesterase
NL195004C (nl) * 1987-03-04 2003-11-04 Novartis Ag Fenylcarbamaat bevattend farmaceutisch preparaat.
IL91398A (en) * 1988-08-30 1994-05-30 Pfizer Pharmaceutical delivery device comprising active substance surrounded by asymmetric membrane
US4984807A (en) * 1990-01-12 1991-01-15 Baruch Shiryon Board game
US5229131A (en) * 1990-02-05 1993-07-20 University Of Michigan Pulsatile drug delivery system
JPH0794379B2 (ja) * 1990-08-07 1995-10-11 ファイザー・インコーポレーテッド 放出製剤における界面重合膜の使用方法
US5407686A (en) * 1991-11-27 1995-04-18 Sidmak Laboratories, Inc. Sustained release composition for oral administration of active ingredient
US5260069A (en) * 1992-11-27 1993-11-09 Anda Sr Pharmaceuticals Inc. Pulsatile particles drug delivery system
US5358502A (en) * 1993-02-25 1994-10-25 Pfizer Inc PH-triggered osmotic bursting delivery devices
PT621032E (pt) * 1993-04-23 2001-01-31 Novartis Ag Dispositivo de distribuicao de libertacao controlada de farmaco
US5500227A (en) * 1993-11-23 1996-03-19 Euro-Celtique, S.A. Immediate release tablet cores of insoluble drugs having sustained-release coating
US5962535A (en) * 1997-01-17 1999-10-05 Takeda Chemical Industries, Ltd. Composition for alzheimer's disease
IL128043A (en) * 1997-05-30 2004-08-31 Osmotica Corp Multi-layered osmotic device for controlled delivery of active agents
GB9711643D0 (en) * 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
EP0999830A1 (en) * 1997-07-01 2000-05-17 Pfizer Inc. Sertraline salts and sustained-release dosage forms of sertraline
SE9704870D0 (sv) * 1997-12-22 1997-12-22 Astra Ab New pharmaceutical formulation I
CZ302888B6 (cs) * 1998-10-01 2012-01-11 Novartis Ag Orální farmaceutický prípravek obsahující rivastigmin a použití rivastigminu
US6632451B2 (en) * 1999-06-04 2003-10-14 Dexcel Pharma Technologies Ltd. Delayed total release two pulse gastrointestinal drug delivery system

Also Published As

Publication number Publication date
ECSP003685A (es) 2002-05-23
CY1107923T1 (el) 2013-09-04
GB9923045D0 (en) 1999-12-01
NO331480B1 (no) 2012-01-16
AR025792A1 (es) 2002-12-11
RU2281758C2 (ru) 2006-08-20
PT1216032E (pt) 2008-04-29
US20060246101A1 (en) 2006-11-02
PE20010568A1 (es) 2001-05-29
DE60037897T2 (de) 2008-12-24
CA2379595A1 (en) 2001-04-05
MY128759A (en) 2007-02-28
DE60037897D1 (de) 2008-03-13
PL354075A1 (en) 2003-12-15
NO20021452D0 (no) 2002-03-22
TR200200683T2 (tr) 2002-07-22
CO5210867A1 (es) 2002-10-30
WO2001022944A8 (en) 2001-07-26
US20110038897A1 (en) 2011-02-17
IL148908A (en) 2010-06-16
CN1213737C (zh) 2005-08-10
PL200822B1 (pl) 2009-02-27
KR100661441B1 (ko) 2006-12-27
SK4132002A3 (en) 2002-10-08
EP1216032A1 (en) 2002-06-26
EP1216032B1 (en) 2008-01-23
AU1019701A (en) 2001-04-30
KR20050100710A (ko) 2005-10-19
HUP0202744A3 (en) 2004-05-28
ES2299438T3 (es) 2008-06-01
CZ301455B6 (cs) 2010-03-10
HUP0202744A2 (hu) 2003-01-28
ATE384517T1 (de) 2008-02-15
CZ20021028A3 (cs) 2002-06-12
BR0014440A (pt) 2002-06-18
IL148908A0 (en) 2002-09-12
AU769646B2 (en) 2004-01-29
JP2003510268A (ja) 2003-03-18
KR20020038778A (ko) 2002-05-23
NZ517335A (en) 2003-10-31
DK1216032T3 (da) 2008-06-02
SK286651B6 (sk) 2009-03-05
ZA200202369B (en) 2002-12-24
WO2001022944A1 (en) 2001-04-05
CN1376058A (zh) 2002-10-23

Similar Documents

Publication Publication Date Title
ATE329584T1 (de) Orale dosiszusammensetzung mit verlängerter freigabe
AR026045A1 (es) Formulaciones de liberacion prolongada de derivados de eritromocina
NO20021540L (no) Sammensetninger med kontrollert frigivelse omfattende nimesulfid
DK0973527T3 (da) Clarithromycinformuleringer med forlænget frigivelse
EP1196147A4 (en) BUILDING COMPOSITIONS
DE60013812D1 (de) Schnellkupplung
DE60038784D1 (de) Schnellkupplung
ATE490327T1 (de) Impfstoffzusammensetzung
DE60008422D1 (de) Pour-on formulierungen
NO993096D0 (no) Orale cyklosporinformuleringer
ATE254907T1 (de) Natriumhydrogendivalproat-formulierungen mit gesteuerter freigabe
DK1142477T3 (da) Sammensætninger med reguleret frigivelse
DE10196204T1 (de) Orale Vorrichtungen
NO20015670D0 (no) Forbedrede farmasöytiske formuleringer
IS6398A (is) Lyfjablöndur
NO20002126L (no) Formulering med forlenget frigjøring
ITMI991826A0 (it) Nuova formulazione orale
NO20020151D0 (no) Veksthormonformuleringer
NO20021452D0 (no) Orale kontrollerte frigivelsesformuleringer
NO20003677D0 (no) Langvarig frigivelses tigabim formuleringer med reduserte bivirkninger
SI1216032T1 (sl) Oralne formulacije s kontroliranim sproščanjem
GB9916958D0 (en) Controlled release formulations
DK1229900T3 (da) Formuleringer med langvarig frigivelse til implantation
SE9904410D0 (sv) Snabbkoppling
GB0011333D0 (en) Controlled release formulations

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees